

## LIST OF FIGURES

<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
Figure 2.1	Network of airways in the lung	12
Figure 2.2	Weibel's model of Airways	12
Figure 2.3	Clearance pathways of particles by alveolar macrophages	16
Figure 2.4	Mechanism of Impaction	18
Figure 2.5	Mechanism of Sedimentation	18
Figure 2.6	Aerosol drug delivery devices	24
Figure 2.7	Impact of mutant cystic fibrosis transmembrane conductance regulator (CFTR) on cellular physiology	36
Figure 2.8	Proposed pathophysiologic cascade for the CF lung disease and the therapeutic interventions targeted at each step	37
Figure 2.9	Wrinkled particles	47
Figure 2.10	Large porous particles	47
Figure 2.11	Pulmospheres	47
Figure 2.12	Pulmosols	47
Figure 4.1	Particle size distribution of freeze dried TB (A) and AMK (B) ALLP determined by laser diffraction	116
Figure 4.2	Particle size distribution of Spray dried TB (A) and AMK (B) ALLP determined by laser diffraction	117
Figure 4.3	DSC thermograms of freeze dried (FD) and spray dried (SD) ALLP of TB (A) and AMK (B)	119
Figure 4.4	Scanning electron micrographs of SD (A) and FD (B) TB-ALLP	120
Figure 4.5	Scanning electron micrographs of SD (A) and FD (B) AMK-ALLP	120
Figure 4.6	3-D surface plots of SD (A) and FD (B) ALLP	121
Figure 4.7	Comparative percent mass distribution of SD and FD-ALLP of TB (A) and AMK (B) in cascade impactor	124
Figure 4.8	3D-Response surface plot (A) and Contour plot (B) showing the effect of the amount of L- leucine (X <sub>1</sub> ) and TB (X <sub>2</sub> ) added on the response Y (FPF)	131
Figure 4.9	3D-Response surface plot (A) and Contour plot (B)	131

	showing the effect of the amount of L- leucine ( $X_1$ ) and AMK ( $X_2$ ) added on the response Y (FPF).	
Figure 4.10	3D-Response surface plot (A) and Contour plot (B) showing the effect of the amount of L- leucine ( $X_1$ ) and poloxamer-188 ( $X_3$ ) added on the response Y (FPF) of TB ALLP	132
Figure 4.11	3D-Response surface plot (A) and Contour plot (B) showing the effect of the amount of L- leucine ( $X_1$ ) and poloxamer-188 ( $X_3$ ) added on the response Y (FPF) of AMK ALLP	132
Figure 4.12	3D-Response surface plot (A) and Contour plot (B) showing the effect of the amount of TB ( $X_2$ ) and poloxamer- 188 ( $X_3$ ) added on the response Y (FPF)	133
Figure 4.13	3D-Response surface plot (A) and Contour plot (B) showing the effect of the amount of AMK ( $X_2$ ) and poloxamer- 188 ( $X_3$ ) added on the response Y (FPF)	133
Figure 5.1	Percentage equilibrium moisture content of the ALLP after storage at different relative humidities (%w/w)	144
Figure 5.2	Effect of humidity on the percent FPF	144
Figure 5.3	Influence of the airflow on the aerosolization properties of TB-ALLP assessed in cascade impactor	145
Figure 5.4	Influence of the airflow on the aerosolization properties of AMK-ALLP assessed in cascade impactor	146
Figure 5.5	Relationship between $1/(\epsilon_n - \epsilon_f)$ and 'n' in Kawakita's Equation	148
Figure 6.1	Stability profile of Assay content of TB (A) and AMK (B) ALLP Vs. Time in months	159
Figure 6.2	Stability profile of water content (% w/w) of TB (A) and AMK (B) ALLP Vs. Time in months	160
Figure 6.3	Stability profile of volume mean diameter ( $\mu\text{m}$ ) of TB (A) and AMK (B) ALLP Vs. Time in months	161

Figure 6.4	Stability profile of emitted dose (%) of TB (A) and AMK (B) ALLP Vs. Time in months	162
Figure 6.5	Stability profile of fine particle fraction (%) of TB (A) and AMK (B) ALLP Vs. Time in months	163
Figure 7.1	Regional deposition of TB/AMK formulations in the rat lung	170
Figure 7.2	Total rat lung Tobramycin concentration Vs Time	172
Figure 7.3	Total rat lung Amikacin concentration Vs Time	172
Figure 7.4	Photomicrographs of alveolar macrophages engulfed of TB(A) and AMK(B) LBF	175
Figure 7.5	Photomicrographs of alveolar macrophages engulfed of TB(A) and AMK(B) ALLP	175
Figure 7.6	Cell recovery from bronchoalveolar lavage fluid administered with TB (A) and AMK(B) formulations	176
Figure 7.7	Haemotoxylin and eosin staining of representative tracheal sections following assisted ventilation (A) and intra tracheal administration of ALLP (B) and LBFs (C)	177
Figure 7.8	Haemotoxylin and eosin staining of representative lung sections following assisted ventilation (A) and intra tracheal administration of ALLP (B) and LBFs (C)	178